Business Description
Almirall SA
NAICS : 325412
ISIN : ES0157097017
Share Class Description:
LBTSF: Ordinary SharesDescription
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.89 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | 3.65 | |||||
Interest Coverage | 7.17 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.04 | |||||
Beneish M-Score | -2.11 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.2 | |||||
3-Year EBITDA Growth Rate | -21.3 | |||||
3-Year Book Growth Rate | -1.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 14.63 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.4 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 97.7 | |||||
14-Day RSI | 90.05 | |||||
6-1 Month Momentum % | 4.51 | |||||
12-1 Month Momentum % | 7.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.56 | |||||
Quick Ratio | 1.94 | |||||
Cash Ratio | 1.21 | |||||
Days Inventory | 474.43 | |||||
Days Sales Outstanding | 99.99 | |||||
Days Payable | 577.5 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | -2.4 | |||||
3-Year Average Share Buyback Ratio | -5.5 | |||||
Shareholder Yield % | 1.99 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.95 | |||||
Operating Margin % | 7.28 | |||||
Net Margin % | 2.42 | |||||
FCF Margin % | 2.77 | |||||
ROE % | 0.81 | |||||
ROA % | 0.51 | |||||
ROIC % | 0.8 | |||||
ROC (Joel Greenblatt) % | 15.03 | |||||
ROCE % | 1.56 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 167.86 | |||||
Forward PE Ratio | 19.19 | |||||
PE Ratio without NRI | 167.86 | |||||
Shiller PE Ratio | 24.36 | |||||
PS Ratio | 4.07 | |||||
PB Ratio | 1.33 | |||||
Price-to-Tangible-Book | 11.32 | |||||
Price-to-Free-Cash-Flow | 146.88 | |||||
Price-to-Operating-Cash-Flow | 24.8 | |||||
EV-to-EBIT | 65.45 | |||||
EV-to-Forward-EBIT | 10.99 | |||||
EV-to-EBITDA | 21.16 | |||||
EV-to-Forward-EBITDA | 9.6 | |||||
EV-to-Revenue | 4.22 | |||||
EV-to-Forward-Revenue | 1.84 | |||||
EV-to-FCF | 152.54 | |||||
Price-to-Projected-FCF | 1.81 | |||||
Price-to-Median-PS-Value | 1.28 | |||||
Price-to-Graham-Number | 6.94 | |||||
Earnings Yield (Greenblatt) % | 1.53 | |||||
FCF Yield % | 0.67 |